Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence
Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver dis...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00474/full |
| _version_ | 1818386926082719744 |
|---|---|
| author | Carolina Mosoni Carolina Mosoni Tommaso Dionisi Tommaso Dionisi Gabriele Angelo Vassallo Gabriele Angelo Vassallo Antonio Mirijello Claudia Tarli Claudia Tarli Mariangela Antonelli Mariangela Antonelli Luisa Sestito Luisa Sestito Maria Margherita Rando Maria Margherita Rando Alberto Tosoni Alberto Tosoni Salvatore De Cosmo Antonio Gasbarrini Giovanni Addolorato Giovanni Addolorato |
| author_facet | Carolina Mosoni Carolina Mosoni Tommaso Dionisi Tommaso Dionisi Gabriele Angelo Vassallo Gabriele Angelo Vassallo Antonio Mirijello Claudia Tarli Claudia Tarli Mariangela Antonelli Mariangela Antonelli Luisa Sestito Luisa Sestito Maria Margherita Rando Maria Margherita Rando Alberto Tosoni Alberto Tosoni Salvatore De Cosmo Antonio Gasbarrini Giovanni Addolorato Giovanni Addolorato |
| author_sort | Carolina Mosoni |
| collection | DOAJ |
| description | Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed. |
| first_indexed | 2024-12-14T04:01:48Z |
| format | Article |
| id | doaj.art-98c504114d444c758706bdef6337aed5 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-14T04:01:48Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-98c504114d444c758706bdef6337aed52022-12-21T23:17:55ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402018-10-01910.3389/fpsyt.2018.00474409615Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First EvidenceCarolina Mosoni0Carolina Mosoni1Tommaso Dionisi2Tommaso Dionisi3Gabriele Angelo Vassallo4Gabriele Angelo Vassallo5Antonio Mirijello6Claudia Tarli7Claudia Tarli8Mariangela Antonelli9Mariangela Antonelli10Luisa Sestito11Luisa Sestito12Maria Margherita Rando13Maria Margherita Rando14Alberto Tosoni15Alberto Tosoni16Salvatore De Cosmo17Antonio Gasbarrini18Giovanni Addolorato19Giovanni Addolorato20“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyEmergency Department, V. Cervello Hospital, Palermo, ItalyDepartment of Medical Sciences, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Medical Sciences, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy“Alcohol Use Disorder and Related Disease” Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyDepartment of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, ItalyAlcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.https://www.frontiersin.org/article/10.3389/fpsyt.2018.00474/fullalcohol use disorderbaclofenalcoholic liver diseaseliver cirrhosisGABA-B receptor |
| spellingShingle | Carolina Mosoni Carolina Mosoni Tommaso Dionisi Tommaso Dionisi Gabriele Angelo Vassallo Gabriele Angelo Vassallo Antonio Mirijello Claudia Tarli Claudia Tarli Mariangela Antonelli Mariangela Antonelli Luisa Sestito Luisa Sestito Maria Margherita Rando Maria Margherita Rando Alberto Tosoni Alberto Tosoni Salvatore De Cosmo Antonio Gasbarrini Giovanni Addolorato Giovanni Addolorato Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence Frontiers in Psychiatry alcohol use disorder baclofen alcoholic liver disease liver cirrhosis GABA-B receptor |
| title | Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence |
| title_full | Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence |
| title_fullStr | Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence |
| title_full_unstemmed | Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence |
| title_short | Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence |
| title_sort | baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis 10 years after the first evidence |
| topic | alcohol use disorder baclofen alcoholic liver disease liver cirrhosis GABA-B receptor |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00474/full |
| work_keys_str_mv | AT carolinamosoni baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT carolinamosoni baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT tommasodionisi baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT tommasodionisi baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT gabrieleangelovassallo baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT gabrieleangelovassallo baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT antoniomirijello baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT claudiatarli baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT claudiatarli baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT mariangelaantonelli baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT mariangelaantonelli baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT luisasestito baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT luisasestito baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT mariamargheritarando baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT mariamargheritarando baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT albertotosoni baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT albertotosoni baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT salvatoredecosmo baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT antoniogasbarrini baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT giovanniaddolorato baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence AT giovanniaddolorato baclofenforthetreatmentofalcoholusedisorderinpatientswithlivercirrhosis10yearsafterthefirstevidence |